Individualized Functional Connectivity Targeting in aiTBS for Depression

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 15, 2023

Primary Completion Date

March 17, 2025

Study Completion Date

March 17, 2027

Conditions
Depressive Disorder, MajorDepressionMood DisordersMental DisorderPsychiatric Disorder
Interventions
PROCEDURE

transcranial magnetic stimulation

Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise. This protocol will be modeled after the FDA cleared Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, but the patented SAINT rsfc targeting algorithm will not be used for either arm.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER